Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Cash & Equivalents (2021 - 2026)

Unicycive Therapeutics filings provide 4 years of Cash & Equivalents readings, the most recent being $26.1 million for Q4 2024.

  • On a quarterly basis, Cash & Equivalents rose 169.48% to $26.1 million in Q4 2024 year-over-year; TTM through Dec 2024 was $26.1 million, a 169.48% increase, with the full-year FY2024 number at $26.1 million, up 169.48% from a year prior.
  • Cash & Equivalents hit $26.1 million in Q4 2024 for Unicycive Therapeutics, down from $32.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $48.9 million in Q1 2024 to a low of $455000.0 in Q4 2022.
  • Median Cash & Equivalents over the past 4 years was $16.6 million (2021), compared with a mean of $20.4 million.
  • Biggest five-year swings in Cash & Equivalents: plummeted 97.26% in 2022 and later skyrocketed 2032.09% in 2023.
  • Unicycive Therapeutics' Cash & Equivalents stood at $16.6 million in 2021, then plummeted by 97.26% to $455000.0 in 2022, then skyrocketed by 2032.09% to $9.7 million in 2023, then soared by 169.48% to $26.1 million in 2024.
  • The last three reported values for Cash & Equivalents were $26.1 million (Q4 2024), $32.3 million (Q3 2024), and $41.8 million (Q2 2024) per Business Quant data.